ESMO 2022 | HER2-low is not a distinct subtype in inflammatory breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the biologic and prognostic significance of HER2-low expression as a predictive biomarker in inflammatory breast cancer (IBC). 276 patients with stage III or IV breast cancer were separated based on HER2-low or HER2-0 status and when controlling for estrogen receptor (ER) status, outcomes in both cohorts were not significantly different. HER2-low expression therefore does not constitute as a distinct subtype. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.